What STEP 9 measured
The 2024 STEP 9 trial randomized 407 adults with obesity and painful knee osteoarthritis to semaglutide or placebo, alongside lifestyle counseling, for 68 weeks. Women made up 81.6% of participants. Average pain scores fell by 41.7 points with semaglutide and 27.5 with placebo; average weight fell by 13.7% and 3.2%, respectively.
Keep the question precise
These results concern pain and weight in a defined population. They do not demonstrate regenerated cartilage or prove that women respond differently from men. S7’s practical reading question is whether a headline names the outcome actually measured. A pain questionnaire and an image of joint structure would address different claims.
Benefits and limits belong together
Adverse events led to permanent discontinuation in 6.7% versus 3.0%; gastrointestinal problems were the most common reason. Novo Nordisk funded the trial. This explanation reviews the indexed abstract, not the complete publisher paper. It is not treatment guidance or evidence that a research-vial product matches the studied medicine. The accompanying joint sculpture is conceptual.